blood

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of *FAS*-demethylation and FAS re-expression, and synergism with FAS-ligand

Viviane Ghanim, Harald Herrmann, Gerwin Heller, Barbara Peter, Emir Hadzijusufovic, Katharina Blatt, Karina Schuch, Sabine Cerny-Reiterer, Irina Mirkina, Heidrun Karlic, Winfried F. Pickl, Sabine Zöchbauer-Müller and Peter Valent

---

Updated information and services can be found at:
http://bloodjournal.hematologylibrary.org/content/119/18/4242.full.html

Articles on similar topics can be found in the following Blood collections
 Myeloid Neoplasia (828 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of *FAS*-demethylation and FAS re-expression, and synergism with FAS-ligand

Viviane Ghanim,[1] Harald Herrmann,[2] Gerwin Heller,[3] Barbara Peter,[2] Emir Hadzijusufovic,[1,4] Katharina Blatt,[1] Karina Schuch,[5] Sabine Cerny-Reiterer,[1,2] Irina Mirkina,[2] Heidrun Karlic,[2,6] Winfried F. Pickl,[5] Sabine Zöchbauer-Müller,[3] and Peter Valent[1,2]

[1]Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; [2]Ludwig Boltzmann Oncology Cluster Vienna, Austria; [3]Department of Internal Medicine I, Division of Clinical Oncology, Medical University of Vienna, Vienna, Austria; [4]Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine, Vienna, Austria; [5]Institute of Immunology, Medical University of Vienna, Vienna, Austria; and [6]Hanusch Hospital, 3rd Medical Department, Vienna, Austria

Aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL) are advanced hematopoietic neoplasms with poor prognosis. In these patients, neoplastic mast cells (MCs) are resistant against various drugs. We examined the effects of 2 demethylating agents, 5-azacytidine and decitabine on growth and survival of neoplastic MCs and the MC line HMC-1. Two HMC-1 subclones were used, HMC-1.1 lacking KIT D816V and HMC-1.2 exhibiting KIT D816V. Both agents induced apoptosis in HMC-1.1 and HMC-1.2 cells. Decitabine, but not 5-azacytidine, also produced a G_2/M cell-cycle arrest in HMC-1 cells. Drug-induced apoptosis was accompanied by cleavage of caspase-8 and caspase-3 as well as *FAS*-demethylation and FAS–re-expression in neoplastic MCs. Furthermore, both demethylating agents were found to synergize with the FAS-ligand in inducing apoptosis in neoplastic MCs. Correspondingly, siRNA against FAS was found to block drug-induced expression of FAS and drug-induced apoptosis in HMC-1 cells. Neither 5-azacytidine nor decitabine induced substantial apoptosis or growth arrest in normal MCs or normal bone marrow cells. Together, 5-azacytidine and decitabine exert growth-inhibitory and proapoptotic effects in neoplastic MCs. These effects are mediated through "FAS–re-expression" and are augmented by the FAS-ligand. Whether epigenetic drugs produce antineoplastic effects in vivo in patients with ASM and MCL remains to be determined. (*Blood*. 2012;119(18):4242-4252)

Introduction

Systemic mastocytosis (SM) is a myeloid neoplasm characterized by pathologic accumulation of mast cells (MCs) in one or more extracutaneous organs.[1,2] Indolent and aggressive variants of SM have been described.[1-5] In most patients, the transforming *KIT* mutation D816V is detectable independent of the category of SM.[6-8] Patients with indolent SM (ISM) have an excellent prognosis with normal or near-normal life expectancy.[1-5,9,10] In patients with aggressive SM (ASM) and mast cell leukemia (MCL), the prognosis is grave,[1-5,9,10] and responses to conventional drugs and most targeted drugs are poor.[1-4,9,11-15] During the past few years, several attempts have been made to define new molecular targets in neoplastic MCs and to establish new treatment concepts for these patients.[16,17]

Abnormal DNA methylation and histone-acetylation are frequently observed in various neoplasms and supposedly contribute to disease evolution and drug resistance.[18-20] In hematologic malignancies, epigenetic abnormalities have been reported in acute and chronic leukemias as well as in myelodysplastic syndromes (MDS).[21-23] Especially in patients with MDS, abnormal methylation of the genome has been described.[21,22] Correspondingly, epigenetically active drugs such as 5-azacytidine and 5-aza-2′deoxycytidine (decitabine) reportedly act as antineoplastic agents in these patients.[23-25] More recent data suggest that demethylating agents also exert beneficial effects in patients in whom neoplastic cells exhibit myeloproliferative and myelodysplastic features, such as chronic myelomonocytic leukemia (CMML), and sometimes even in patients with advanced myeloproliferative neoplasms (MPN).[26,27] Advanced SM is a myeloid neoplasm that often presents with myeloproliferative features and sometimes with bone marrow (BM) dysplasia.[1-5] In addition, advanced SM may coexist with MDS (SM-MDS), CMML, or a *JAK2*-mutated MPN.[28]

However, so far, no data on the effects of demethylating agents on neoplastic cells in advanced SM or SM-AHNMD are available. In addition, little is known about methylation patterns in neoplastic MCs. We explored the effects of 2 widely used demethylating agents, 5-azacytidine and decitabine, on growth and survival of neoplastic MCs, and examined the mechanism(s) of action of these drugs.

Methods

Drugs, monoclonal antibodies, and other reagents

PKC412 (midostaurin) was kindly provided by Dr J. Roesel and Dr P. W. Manley (Novartis). 5-azacytidine, decitabine, recombinant human FAS-ligand, and propidium iodide (PI) were purchased from Sigma-Aldrich,

RPMI 1640 medium and FCS from PAA Laboratories, IMDM from Gibco Life Technologies, and ^{3}H-thymidine from Perkin Elmer. The phycoerythrin (PE)–labeled monoclonal antibody (mAb) WM15 (CD13), DX2 (CD95), 104D2 (CD117), N6B6 (CD164), C92605 (anti-active caspase-3), pS473 (anti-pAkt), and the Alexa fluor647-labeled mAb pY694 (anti-pSTAT5), and N7548 (anti-p-S6) were from BD Biosciences, annexin V–FITC from Biosciences, and FITC-labeled CLBGran/12 mAb (CD63) from Beckman Coulter.

Isolation and culture of neoplastic cells

Primary neoplastic cells were obtained by BM aspiration (diagnostic samples) in 6 patients with SM (ISM, n = 4; ASM, n = 1; SM-AHNMD, n = 1) after informed consent was given. In patients with ASM and SM-AHNMD, a majority of peripheral blood and BM leukocytes were found to carry KIT D816V, confirming previous observations.[4,6] The patients' characteristics are shown in supplemental Table 1 (available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). Diagnoses were established according to published criteria.[3-5] Ficoll-isolated BM mononuclear cells (MNCs) were cultured in RPMI 1640 medium containing 10% FCS and antibiotics (5% CO_2, 37°C). Normal BM cells were obtained from 3 lymphoma patients without BM involvement (routine staging). Cultured normal MCs were generated from CD133[+] cord blood progenitors using IL-3, IL-6, and stem cell factor (SCF) as described.[29] All studies were approved by the Local Ethics Committee of the Medical University of Vienna. The MC line HMC-1[30] was kindly provided by Dr J. H. Butterfield (Mayo Clinic). Two subclones were used, HMC-1.1 harboring KIT V560G, and HMC-1.2 harboring KIT V560G as well as KIT D816V.[31] HMC-1 cells were cultured in IMDM with 10% FCS and antibiotics. Additional cell lines used in this study were HL60, U937, KG1, KU812, and K562. These cell lines were cultured in RPMI 1640 medium with 10% FCS and antibiotics (5% CO_2, 37°C).

Treatment with pharmacologic inhibitors and measurement of proliferation

Primary neoplastic MCs and HMC-1 cells were cultured in control medium or in various concentrations of 5-azacytidine (1-20μM), decitabine (1-20μM), or PKC412 (50-110nM) for 48, 72, or 96 hours. In select experiments, demethylating agents were applied in the absence or presence of FAS-ligand (1 ng/mL) or PKC412 (200nM). Proliferation was determined by ^{3}H-thymidine as reported[32,33] with the following modification: before addition of ^{3}H-thymidine, cells were washed in phosphate-buffered saline (PBS) because in control experiments we found that 5-azacytidine competes with ^{3}H-thymidine in the uptake process (supplemental Figure 1). All experiments were performed in triplicates. In a separate set of experiments, combinations of PKC412 and demethylating agents at suboptimal concentrations (with fixed ratio of drug-concentrations) were applied on HMC-1 cells.

Western blot experiments

HMC-1 cells were incubated with control medium, 5-azacytidine (5μM) or decitabine (5μM) for 48 hours. Then, Western blotting (WB) was performed as described[32,33] using a polyclonal antibody against cleaved caspase-3 or mAb 18C8 against cleaved caspase-8 (Cell Signaling Technology). To confirm equal loading, a polyclonal antibody against β-actin (Sigma-Aldrich) was used. Antibody-reactivity was made visible by donkey antirabbit immunoglobulin (Ig)G and lumingen PS-3 detection reagent (GE-Healthcare).

Evaluation of apoptosis by morphology and TUNEL assay

HMC-1 cells were incubated with various concentrations of 5-azacytidine (1-20μM), decitabine (1-20μM), or control medium at 37°C for 48 or 96 hours. In select experiments, drugs were applied in the absence or presence of FAS-ligand (1 ng/mL). The percentage of apoptotic cells was quantified on Wright-Giemsa–stained cytospin slides. In TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling) assay experiments, cells were cultured in medium without or with demethylating agents

(5-azacytidine, 5μM or decitabine, 5μM) for 96 hours. The TUNEL assay was performed as reported[32,33] using the In situ cell death detection kit-fluorescein (Roche Diagnostics). Cells were analyzed with a Nikon Eclipse E 800 fluorescence microscope or a Carl Zeiss Imager A1 microscope (Carl Zeiss).

Flow cytometry experiments

To determine the effects of 5-azacytidine and decitabine on expression of surface antigens (CD13/aminopeptidase-N, CD63/LAMP-3, CD95/FAS, CD117/KIT, and CD164/endolyn) or cytoplasmic molecules (pAkt, pS6, pSTAT3, pSTAT5, activated caspase-3) in HMC-1 cells, flow cytometry was performed on a FACScalibur (Becton Dickinson). Cells were incubated in control medium, 5-azacytidine (1-20μM), or decitabine (1-20μM) at 37°C for 4, 24, or 48 hours (signaling molecules), or for 48 or 96 hours (surface molecules and caspase-3). Before staining with mAbs against cytoplasmic molecules, HMC-1 cells were fixed in 2% formaldehyde and permeabilized using ice-cold methanol (−20°C, 10 minutes). Apoptosis was measured by combined annexin V/propidium iodide staining[32-34] after exposure of MCs to 5-azacytidine or decitabine (each 1-20μM) for 48 or 96 hours (37°C). In select experiments, HMC-1 cells were cultured in the presence or absence of FAS-ligand (1 ng/mL) or PKC412 (70-200nM) before being analyzed for cell viability. Cell-cycle distribution was analyzed as reported.[34] In these experiments, HMC-1 cells were incubated with 5-azacytidine or decitabine (each 1-20μM) for 96 hours (37°C).

Quantitative RT-PCR

HMC-1 cells were incubated with or without 5-azacytidine (5μM) or decitabine (5μM) at 37°C for 48 or 96 hours. Then, RNA was isolated using Omniscript Reverse Transcriptase kit or RNeasy MinElute Cleanup Kit (QIAGEN) according to the manufacturer's instructions. Real-time polymerase chain reaction (PCR) for *FAS, p16, p21, Bid, Puma, Noxa, Bad, Bim*, and *ABL* was performed using specific primers (supplemental Table 2). mRNA levels were quantified on a 7900HT Fast real-time PCR System (Applied Biosystems) using iTAq SYBR Green Supermix with ROX (Bio-Rad). FAS, p16, p21, Bid-, Puma-, Noxa-, Bad-, and Bim mRNA expression levels were expressed as percentage of ABL mRNA. In select experiments, expression of transcripts specific for *FAS, p16*, and *p21* were quantified by quantitative (q) PCR using TaqMan Gene Expression assay using the ABI PRISM-7000 system (Applied Biosystems) as reported.[34] *GAPDH* served as housekeeping gene. Results were expressed as fold-induction compared with medium control.

Isolation of genomic DNA and methylation-specific PCR

Genomic DNA was isolated from untreated and drug-exposed HMC-1 cells and untreated normal BM cells by digestion with proteinase K, followed by phenol-chloroform extraction and ethanol precipitation.[35] Genomic DNA (1 μg) was modified by treatment with sodium bisulfite using QIAGEN EpiTect Bisulfite kit according to the manufacturer's instructions. The 5′ methylation status of *p15 (CDKN2B)*, *p16 (CDKN2A)*, *p21 (CDKN1A)*, and *FAS* was determined by methylation-specific PCR (MSP). Primer sequences and PCR conditions for *p15* and *p16* were the same as previously described.[36] MSP primer sequences for *p21* were designed using Methyl Primer Express Version 1.0 (Applied Biosystems) and are shown in supplemental Table 3. Primer sequences and MSP conditions for evaluation of *FAS* were prepared according to methPrimerDB (http://medgen.ugent.be/methprimerdb/index.php, ID:136). EpiTect methylated control DNA (QIAGEN) was used as positive control for methylated alleles. Water blanks were used as negative control. PCR products were resolved on a 2% agarose gel and stained with GelRed (Biotium).

Bisulfite genomic sequencing of the *FAS promoter*

Part of the *FAS* CpG island (CGI) was amplified using methylation-insensitive PCR primers. Primer sequences were designed using Methyl Primer Express Version 1.0 software and are shown in supplemental Table 3. PCR was performed on sodium bisulfite converted genomic DNA. PCR products were gel-purified and cloned using TOPO TA Cloning Kit for

Figure 1. 5-azacytidine and decitabine induce apoptosis in neoplastic MCs. (A-B) HMC-1.1 cells and HMC-1.2 cells were incubated in control medium (Co) or in medium containing various concentrations (1-20μM) of 5-azacytidine or decitabine at 37°C for 48 hours (gray bars) or 96 hours (black bars). After incubation, apoptotic cells were quantified by either light microscopy (A) or by flow cytometry using an antibody against active caspase-3 (B). Results show the percentage of apoptotic cells and active caspase-3-positive cells, and represent the mean ± SD of 5 independent experiments (*$P < .05$ compared with control). (C) BM-derived MCs from a patient with ASM were cultured in the presence or absence (Co) of various concentrations of 5-azacytidine or decitabine at 37°C for 48 hours (gray bars) or 96 hours (black bars). Results show the percentage of apoptotic cells determined by light microscopy.

Sequencing (Invitrogen). PCR amplification for sequencing was performed using M13 primers. Three clones from each cell sample were sequenced. In total, 18 CpG sites located between nucleotide (nt) 90750233 and nt 90750773 of chromosome 10 were analyzed for methylation. The percentage of methylation was calculated as number of methylated CpG sites relative to the total number of CpG sites. Differences in the extent of methylation between HMC-1 cells and control BM cells were assessed statistically by applying the Fisher exact test and the χ^2 test.

EpiTect methyl qPCR array analysis and methylation-sensitive high resolution melting analysis

Genomic DNA (1 μg) from HMC-1.2 cells and normal BM cells was digested using EpitTect methyl DNA restriction Kit (QIAGEN) according to the manufacturer's instructions. Apoptosis EpiTect methyl qPCR arrays and tumor suppressor gene EpiTect methyl qPCR Arrays (QIAGEN) were applied. Real-time PCR was performed using RT2 SYBR Green ROX qPCR Mastermix (QIAGEN) according to the manufacturer′s recommendations in a 96-well ABI StepOne system (Applied Biosystems). Cycle threshold (Ct) values were used to calculate the percentages of hypermethylated (HM), unmethylated (UM), and intermediately methylated (IM) DNA according to the recommendation of the manufacturer (QIAGEN). For methylation-sensitive high resolution melting (MS-HRM) analyses, sodium bisulfite-treated genomic DNA was used. Primer sequences (supplemental Table 3) were designed using Methyl Primer Express Version 1.0 software. MS-HRM analyses were performed using EpiTect HRM PCR kit in a RotorGeneQ cycler (QIAGEN) as described.[37]

Application of siRNA against FAS/CD95

siRNAs directed against FAS or against luciferase (supplemental Table 2) were synthesized in 2′-deprotected, duplexed, and desalted form by Dharmacon and transfected into HMC-1.1 and HMC-1.2 cells using

lipofectin (Invitrogen) as described.[33] In brief, cells were exposed to lipofectin (75nM) and siRNA (200nM) in serum-free IMDM at 37°C for 4 hours. The siRNA-induced knockdown of FAS (CD95) in HMC-1 cells was confirmed by flow cytometry. siRNA-treated cells were cultured in control medium in the presence or absence of 5-azacytidine (5μM) or decitabine (5μM) for 30 hours, and were then examined for signs of apoptosis and expression of active caspase-3 by flow cytometry.

Statistical analyses

To determine the significant differences in growth and survival of cells after exposure to control medium or inhibitors, the student t test for dependent samples was applied. The Fisher exact test and the χ^2 test were applied to define difference in methylation of the *FAS* promoter in normal and neoplastic cells. Results were considered statistically significant when P is less than .05.

Results

5-azacytidine and decitabine induce apoptosis in neoplastic MCs

As assessed by light microscopy, 5-azacytidine and decitabine were found to induce apoptosis in HMC-1.1 cells and HMC-1.2 cells (Figure 1A). The effects of both drugs were dose-dependent. In case of decitabine, drug effects were more pronounced after 96 hours than after 48 hours (Figure 1A). The dose-dependent effects of 5-azacytidine and decitabine on survival of HMC-1 cells were confirmed by measuring active caspase-3 levels by flow cytometry (Figure 1B). We were also able to show that 5-azacytidine

Figure 2. 5-azacytidine and decitabine induce expression of active caspase-8 and active caspase-3 in neoplastic MCs. (A) HMC-1.1 and HMC-1.2 cells were incubated in control medium or in medium containing 5-azacytidine (5μM) or decitabine (5μM) at 37°C for 96 hours. Then, Western blotting was performed using antibodies against cleaved caspase-8 and cleaved caspase-3. To confirm equal loading, a polyclonal antibody against β-actin was applied. (B) Cord blood progenitor-derived normal MCs and HMC-1 cells were cultured in the presence of control medium (left panels), 5-azacytidine (5μM; middle panels), or decitabine (5μM; right panels) at 37°C for 96 hours. Then, cells were analyzed by annexin V/PI staining. Results show the percentage of annexin V/PI-positive cells determined by flow cytometry. (C) HMC-1.1 cells and HMC-1.2 cells were incubated in control medium (Co) or in medium containing 5-azacytidine (5μM) or decitabine (5μM) at 37°C for 96 hours. After incubation, the presence of apoptotic cells was determined by TUNEL assay.

and decitabine induce apoptosis in primary neoplastic MCs in a patient with ASM (Figure 1C). In our WB experiments, 5-azacytidine and decitabine induced cleavage of caspase-3 and caspase-8 in both HMC-1 subclones (Figure 2A). Moreover, we were able to confirm drug-induced apoptosis in HMC-1 cells by annexin V staining (Figure 2B) and by a TUNEL assay (Figure 2C). In normal cultured MCs, the demethylating agents did not induce apoptosis (Figure 2B).

5-azacytidine and decitabine promote expression of FAS in neoplastic MCs

As determined by flow cytometry, 5-azacytidine and decitabine were found to promote expression of FAS/CD95 in HMC-1.1 and HMC-1.2 cells (Figure 3A), whereas PKC412 showed no effects on FAS expression (not shown). FAS-promoting effects of both demethylating drugs were seen after 48 and 96 hours (Figure 3B), and were confirmed by qPCR (supplemental Table 4). The other surface molecules examined (CD13, CD63, CD117, CD164) were not up-regulated by the 2 demethylating agents applied. Rather, 5-azacytidine and decitabine were found to slightly down-regulate the expression of KIT/CD117 in HMC-1.1 and HMC-1.2 cells (Figure 3C). 5-azacytidine and decitabine failed to promote FAS expression in normal MCs (Figure 3A). We next asked whether 5-azacytidine or decitabine would cause deactivation of KIT-

downstream signaling molecules in neoplastic MCs. However, no effects of 5-azacytidine or decitabine on expression of pAkt, pS6, pSTAT3, or pSTAT5 in HMC-1 cells were seen (supplemental Figure 2).

5-azacytidine and decitabine revert DNA hypermethylation in HMC-1 cells and lead to demethylation of the *FAS* promoter and thus to FAS expression

As determined by MSP, *p16* and *FAS* were found to be hypermethylated in HMC-1.1 cells and HMC-1.2 cells (Figure 4A) but not in normal BM cells (Figure 4B). Interestingly, *p21* was found to be hypermethylated in HMC-1.2 cells but not in HMC-1.1 cells, and *p15* was neither hypermethylated in HMC-1.1 nor in HMC-1.2 cells (Figure 4A). Bisulfite genomic sequencing (BGS) confirmed that the *FAS* promoter is hypermethylated in HMC-1 cells but not in normal BM cells (Figure 4C). Both 5-azacytidine and decitabine were found to induce demethylation of *FAS* in HMC-1.1 cells and HMC-1.2 cells (Figure 4A). By contrast, no effects of these drugs on methylation of *p16* or *p21* were seen (Figure 4A). In both qPCR protocols applied, we were able to show that 5-azacytidine and decitabine promote FAS mRNA expression in HMC-1 cells (Figure 4D, supplemental Table 4). To define the specificity of these drug effects, we examined the effects of 5-azacytidine and decitabine on expression of other proapoptotic molecules known to

Figure 3. Effects of 5-azacytidine and decitabine on expression of FAS (CD95) in neoplastic MCs. (A) Cord blood progenitor-derived MCs and HMC-1 cells were cultured in control medium (open histograms) or in the presence of 5-azacytidine (5μM) or decitabine (5μM; gray histograms) at 37°C for 96 hours. Thereafter, CD95 expression was analyzed by flow cytometry. As visible, the demethylating agents promoted FAS expression in neoplastic MCs but not in normal MCs. (B) HMC-1 cells were cultured in the absence (Co) or presence of 5-azacytidine or decitabine (each 5μM) for 48 hours (gray bars) or 96 hours (black bars). Then, expression of CD95 was analyzed by flow cytometry. Drug-induced up-regulation of CD95 was calculated from mean fluorescence intensities (MFIs) obtained with treated (MFIstim) and untreated (MFIco) cells, and is expressed as stimulation index = SI (MFIstim:MFIco). Results show SI values and represent the mean ± SD of 3 independent experiments (*$P < .05$ compared with control). (C) HMC-1 cells were exposed to various concentrations of 5-azacytidine or decitabine (1-20μM) at 37°C for 48 hours (gray bars) or 96 hours (black bars). Then, cells were washed and stained with antibodies against CD117/KIT and analyzed by flow cytometry. Drug-induced down-regulation of KIT was expressed as SI (MFIstim:MFIco). Results represent the mean ± SD of 3 independent experiments (*$P < .05$ compared with control).

play a role in survival of neoplastic MCs. We found that Bad and Bid are not up-regulated by exposure to 5-azacytidine or decitabine in these experiments, and that decitabine slightly promotes the expression of p21 mRNA, Noxa mRNA, and Bim mRNA, in both HMC-1 subclones (supplemental Tables 4-5).

Methylation analyses of other apoptosis-related and tumor suppressor antigens

In a next step, we determined the methylation status of 24 classic apoptosis-associated genes and 24 classic tumor suppressor genes (TSGs) in HMC-1.2 cells and in control (normal BM) cells using a commercially available methylation qPCR array. The 48 genes analyzed are shown in supplemental Figure 3. Seven apoptosis-associated genes (*CIDEB*, *GADD45A*, *HRK*, *TNFRSF25*, *BIK*, *BID*, and *TNFRSF21*) and 6 TSG (*NEUROG1*, *CDH1*, *GSTP1*, *CDH13*, *TP73*, and *WIF1*) were found to be methylated in HMC-1.2 cells but not in normal BM cells, suggesting that these genes are aberrantly hypermethylated in neoplastic MCs. Next, 2 genes (*CIDEB* and *NEUROG1*) hypermethylated in HMC-1.2 cells but not in normal BM cells and 1 gene (*PDLIM4*) hypermethy-

lated in both cell types, were subjected to MS-HRM analyses to confirm qPCR array results (supplemental Figure 3). Methylation qPCR data and MS-HRM data were found to be highly comparable (Pearson correlation coefficient = 0.984; $P < .001$). In a next step, we examined the effects of 5-azacytidine, and decitabine on the methylation status of these genes. Using MS-HRM analysis, we observed a (slight) demethylating effect of 5-azacytidine on *CIDEB*, *NEUROG1,* and *PDLIM4* (reduction of methylation by approximately 10%), and a slight demethylating effect (approximately 6%) of decitabine on *CIDEB*.

5-azacytidine and decitabine cooperate with FAS-ligand in inducing apoptosis in neoplastic MCs

5-azacytidine and decitabine were found to cooperate with FAS-ligand in producing apoptosis in HMC-1 cells (Figure 4E-F, supplemental Figure 4). However, interestingly only a slight cooperative effect was seen when proliferation was analyzed (supplemental Figure 5). In the absence of demethylating agents, FAS-ligand did not induce apoptosis (Figure 4E-F). We also examined whether FAS-ligand and the demethylating agents tested

would exert cooperative antineoplastic effects in other myeloid neoplasms. However, in all other cell line models examined, including 3 acute myeloid leukemia (AML) cell lines (HL60, U937, KG1) and 2 chronic myeloid leukemia (CML) cell lines (K562, KU812), no cooperative effects of the drug combinations tested were seen (supplemental Figures 6-7).

siRNA-induced knockdown of FAS in neoplastic MCs leads to resistance against 5-azacytidine and decitabine

To further confirm that FAS is a relevant death regulator involved in drug-induced growth inhibition and apoptosis in neoplastic MCs, we performed experiments using FAS-specific siRNA. The siRNA-induced knockdown of FAS was confirmed by flow cytometry (supplemental Figure 8). In both HMC-1 subclones, transfection with siRNA was found to lead to resistance against 5-azacytidine and decitabine. In fact, both drugs were unable to induce FAS expression (Figure 5A) or apoptosis (Figure 5B-C) in cells transfected with FAS-specific siRNA (Figure 5A-C). Moreover, FAS siRNA-transfected cells were found to be unresponsive against the growth-inhibitory effects of 5-azacytidine and decitabine (not shown). By contrast, FAS siRNA-transfected cells were still responsive to PKC412 in the same way as nontransfected cells (not shown).

5-azacytidine and decitabine exert differential effects on cell cycle progression and proliferation in HMC-1 cells

We next examined drug effects on cell-cycle progression and proliferation in HMC-1 cells. As visible in Figure 6A, decitabine was found to induce a G_2/M cell cycle arrest in HMC-1 cells, whereas no effects were seen with 5-azacytidine. Corresponding results were obtained in a proliferation assay. In particular, as determined in proliferation experiments, decitabine was found to inhibit ^{3}H-thymidine uptake, and thus the proliferation of HMC-1 cells in a dose-dependent manner with comparable IC_{50} values obtained in the 2 subclones (1-5μM; Figure 6B), whereas 5-azacytidine showed less pronounced growth-inhibitory effects in HMC-1 cells (IC_{50}: 10-20μM; Figure 6B). We also confirmed the growth-inhibitory effects of 5-azacytidine and decitabine in primary neoplastic MCs. As visible in Figure 6C, 5-azacytidine and decitabine were found to inhibit ^{3}H-thymidine uptake in primary neoplastic cells in all patients examined, including one with ISM, one with ASM, and one with SM-CMML. In the patients with ASM and SM-AHNMD, most cells in the test sample were found to express KIT D816V. Similar to HMC-1 cells, the effects of decitabine on proliferation of primary MCs were more pronounced compared with effects seen with 5-azacytidine (Figure 6C). In normal BM cells, no growth-inhibitory effects of 5-azacytidine or decitabine were found (Figure 6D).

Cooperative effects of demethylating agents and PKC412 on growth of neoplastic MCs

Because demethylating agents did not alter KIT expression or KIT downstream signaling in HMC-1 cells, we screened for cooperative or even synergistic antineoplastic effects of the KIT D816V-blocker PKC412 and the demethylating agents tested. We found that PKC412, when applied at a constant dose (200nM), promotes the growth-inhibitory effects of both 5-azacytidine and decitabine in HMC-1 cells (supplemental Figure 9). These effects were mostly additive but not synergistic. Moreover, no synergistic effects of 5-azacytidine or decitabine and PKC412 on survival of HMC-1 cells were seen (supplemental Figure 9).

Discussion

Demethylating agents are increasingly used to treat patients with high risk MDS or other advanced myeloid neoplasms.[21-27] Although advanced SM is considered a myeloproliferative neoplasm and is sometimes accompanied by an overt MDS or CMML,[3-5,28] the disease has so far not been studied in the context of epigenetic mechanisms or epigenetically active drugs. Here, we describe that 5-azacytidine and decitabine induce apoptosis in neoplastic MCs, and that both drugs induce *FAS* demethylation and surface expression of FAS in MCs. Moreover, both drugs were found to inhibit proliferation and to cooperate with the FAS-ligand in producing apoptosis in neoplastic MCs. The proapoptotic effects of 5-azacytidine and decitabine were seen in HMC-1 cells as well as in primary neoplastic MCs, but not in normal human MCs. These data would be in favor of new treatment concepts using demethylating agents in advanced SM, that is, ASM and MCL.

Apoptosis-inducing effects of 5-azacytidine and decitabine were demonstrable by microscopy, annexin V staining, and by a TUNEL assay. Moreover, we were able to show that both drugs induce caspase-3 and caspase-8 cleavage in HMC-1 cells. The drug concentrations required to produce apoptosis were found to be in a pharmacologically meaningful range, and were similar to concentrations required for induction of apoptosis in other myeloid cells.[38-40] An interesting observation was that 5-azacytidine and decitabine induce apoptosis in both HMC-1 subclones, namely HMC-1.1 cells lacking KIT D816V and HMC-1.2 cells expressing KIT D816V, with comparable efficacy. This is of importance because KIT D816V is expressed in neoplastic MCs in a majority of patients with advanced SM[6-8] and introduces resistance against KIT tyrosine kinase blockers.[31,32] In all, the application of demethylating agents in ASM and MLC may be an interesting approach. In this regard it is also important to state that neither 5-azacytidine nor decitabine were found to induce apoptosis in normal MCs or normal BM cells.

So far, little is known about the methylation profile of neoplastic MCs in systemic mastocytosis or MCL. In this study, we found that a number of classic apoptosis-related genes, including *FAS*, and several TSG, including *p16* and *p21*, are hypermethylated in HMC-1 cells. Interestingly, *p16* and *FAS* were found to be hypermethylated in both HMC-1 subclones, whereas *p21* was found to be hypermethylated only in HMC-1.2 cells, but not in HMC-1.1 cells.

Demethylating agents exert growth-inhibitory and proapoptotic effects on cancer cells through multiple mechanisms, including demethylation and subsequent reexpression of critical TSGs or modulation of other critical target genes.[18-20,38-40] In this study, we asked whether the methylation-status of the identified, hypermethylated TSG or apoptosis-related genes in HMC-1 cells is modulated by 5-azacytidine and/or decitabine. As assessed by MS-HRM analysis, 5-azacytidine was found to exert slight demethylating effects on *CIDEB*, *NEUROG1,* and *PDLIM4*, and decitabine produced a mild demethylating effect on *CIDEB*. However, the most impressive observation was, that both drugs exert profound demethylating effects on *FAS* in both HMC-1 subclones. We also found that 5-azacytidine and decitabine induce reexpression of the FAS protein in HMC-1 cells. Two other proapoptotic death regulators, Bim and Noxa, were also found to increase on exposure to decitabine in HMC-1 cells, but these drug effects did not reach

Figure 4. Effects of 5-azacytidine and decitabine on the 5′methylation status of *FAS* and FAS mRNA expression levels in neoplastic MCs. (A) HMC-1 cells were exposed to control medium (untreated), 5-azacytidine (5μM) or decitabine (5μM) for 96 hours. Then, the 5′methylation status of *p15*, *p16*, *p21*, and *FAS* was determined by MSP. EpiTect-methylated control DNA was used as positive-control. Vertical lines have been inserted to indicate a repositioned gel lane. (B) 5′methylation status of *p15*, *p16*, *p21*, and *FAS* in normal BM cells in 2 donors (#1 and #2) determined by MSP. To verify efficient sodium bisulfite conversion, we also performed unmethylated specific PCR (USP) for *p15*, *p16*, *p21*, and *FAS*. EpiTect-methylated and unmethylated control DNA were used as positive-control. (C) BGS of a part of the *FAS* CGI was performed as previously described using HMC-1.1 cells, HMC-1.2 cells, and normal BM cells. Black squares indicate methylated cytosines at CpG sites, and white squares represent unmethylated cytosines at CpG sites. Whereas in HMC-1.1 cells, 80% of all cytosines at CpG sites analyzed were methylated, 15% of all cytosines at CpG sites analyzed were methylated in HMC-1.2 cells. No methylation was detected in normal BM cells. The percentage of methylation and the significance by Fisher exact test (A) and χ² test (B) are shown. The bottom panel shows representative chromatograms from BGS in HMC-1.1 cells, HMC-1.2 cells, and normal BM cells. Sites for methylation are underlined. Asterisks indicate cytosines that were converted to thymine. (D) HMC-1.1 and HMC-1.2 cells were incubated in control medium, 5-azacytidine (5μM) or decitabine (5μM) at 37°C for 48 hours (gray bars) or 96 hours (black bars). Thereafter, FAS mRNA expression was analyzed by qPCR. GAPDH served as a reference gene. Results show the

Figure 5. Effects of FAS siRNA on drug-induced FAS expression in HMC-1 cells and responsiveness against demethylating agents. (A) HMC-1.2 cells were kept in control medium (untransfected cells) or were transfected with siRNA against FAS (200nM) using lipofectin. Cells were then incubated in control medium (black-lined open histograms), 5-azacytidine, or decitabine (each 5µM, gray histograms) at 37°C for 30 hours. Thereafter, CD95 expression was analyzed by flow cytometry. Expression of FAS was compared with staining reactions produced by isotype-matched control antibodies (gray-lined open histograms). (B-C) HMC-1.2 cells were kept in control medium (untransfected cells) or were transfected with siRNA against luciferase (200nM) or against FAS (200nM) using lipofectin. After 1 hour, cells were incubated in control medium, 5-azacytidine, or decitabine (each 5µM) at 37°C for 30 hours. After incubation, annexin V/PI staining (B) or active caspase-3 staining (C) was performed by flow cytometry. Results show the percentage of annexin V/PI-positive cells determined by flow cytometry (B), and the percentage of active caspase-3–positive cells (C).

statistical significance. All in all, these results suggest that hyper-methylated *FAS* may be a major target of 5-azacytidine and decitabine in neoplastic MCs.

To confirm this hypothesis, we asked whether FAS reexpression in neoplastic MCs is of functional significance and responsible for drug-induced apoptosis. To address this question, we applied siRNA against FAS. The siRNA-induced knockdown of FAS in HMC-1 cells resulted in resistance against 5-azacytidine and decitabine. In particular, siRNA-transfected cells were no longer able to up-regulate FAS and to undergo apoptosis on exposure to 5-azacytidine or decitabine. These data strongly suggest that 5-azacytidine and decitabine exert proapoptotic effects on MCs via FAS reexpression, and that FAS is a critical death regulator in neoplastic MCs. Interestingly, only a few data are available about *FAS* hypermethylation and FAS reexpression induced by demethy-

lating agents in other cancer types. In one study, *FAS* has been described to be hypermethylated in colon cancer cells, and decitabine was found to lead to demethylation of *FAS* in neoplastic cells.[41] To the best of our knowledge, our report is the first to demonstrate epigenetic regulation of *FAS* in neoplastic MCs, and that demethylating agents induce FAS expression and thereby apoptosis in these cells.

A number of previous and more recent data suggest that decitabine induces a cell-cycle arrest in various neoplastic cells, whereas 5-azacytidine is usually less effective.[38,42-47] In line with these observations, we found that decitabine, but not 5-azacytidine, is capable of inducing cell cycle arrest in HMC-1.1 and HMC-1.2 cells. Moreover, we found that decitabine, and less effectively 5-azacytidine, inhibit the proliferation of HMC-1 cells. The effects of decitabine on growth of neoplastic MCs were dose-dependent

Figure 4 (continued) fold-increase of mRNA expression and represent the mean ± SD of 3 independent experiments (*P < .05 compared with control). (E) HMC-1 cells were incubated with control medium, 5-azacytidine, or decitabine (each 5µM) in the absence or presence of FAS-ligand (1 ng/mL) for 96 hours. Then, annexin V/PI staining was performed. Results show the percentage of annexin V/PI+ cells. (F) HMC-1 cells were incubated in control medium, 5-azacytidine, or decitabine (each 5µM) in the absence (black bars) or presence (gray bars) of FAS-ligand (1 ng/mL) for 96 hours. Then, the numbers (percentage) of active caspase-3–positive cells were assessed by flow cytometry. Results show the mean ± SD of 3 independent experiments.

Figure 6. Effects of 5-azacytidine and decitabine on proliferation of neoplastic MCs and normal BM cells. (A) HMC-1.1 and HMC-1.2 cells were incubated in control medium (Co) or various concentrations of 5-azacytidine or decitabine (37°C, 96 hours). Thereafter, cell-cycle distribution was measured by flow cytometry using PI. The percentage of cells in G_0/G_1 phase (black bars), G_2/M phase (gray bars), and S phase (open bars) are shown. Results represent the mean ± SD of 3 independent experiments (*$P < .05$ compared with control). (B) HMC-1 cells were incubated in control medium (Co) or various concentrations of 5-azacytidine or decitabine at 37°C for 48 hours. Thereafter, ^{3}H-thymidine uptake was determined. Results show the percentage of ^{3}H-thymidine uptake compared with control (Co on x axis = 100%) and represent the mean ± SD of 5 independent experiments (*$P < .05$ compared with control). (C-D) Primary neoplastic cells from patients with systemic mastocytosis, SM (ISM, SM-CMML, and ASM [C]), or normal BM cells (D) were incubated in control medium (Co) or various concentrations of 5-azacytidine or decitabine (37°C, 48 hours). Then, ^{3}H-thymidine uptake was measured. Results show percent ^{3}H-thymidine uptake compared with control. Data obtained in HMC-1 cells (B) represent the mean ± SD from 3 independent experiments, and data obtained with primary cells (C-D) represent the mean ± SD from triplicates (*$P < .05$ compared with control).

and were also seen in primary neoplastic MCs obtained from patients with indolent SM, ASM, and SM with associated CMML. Again IC$_{50}$ values were found to be within a pharmacologically meaningful range. An important point in our experiments was to adapt the ^{3}H-thymidine uptake assay to the drug-type analyzed. In fact, in pilot experiments we found that 5-azacytidine directly interferes with ^{3}H-thymidine uptake. Therefore, cells had to be washed thoroughly before adding ^{3}H-thymidine. However, after thorough washing, results were comparable in all assays and all control conditions analyzed.

Recent data suggest that interactions between FAS and the FAS-ligand support apoptosis in neoplastic cells.[41,48,49] We asked whether the FAS-ligand promotes drug-induced apoptosis in neoplastic MCs. In these experiments we found that the FAS-ligand per se does not induce growth inhibition or apoptosis in neoplastic MCs. However, the FAS-ligand was found to promote 5-azacytidine–induced and decitabine-induced apoptosis in neoplastic MCs. These data suggest that FAS is an inducible death regulator in neoplastic MCs, which may act as a more potent proapoptotic cofactor in drug-exposed cells when interacting with

the FAS-ligand, an observation that may have clinical implications. We therefore asked whether the cooperative inhibitory effects of the FAS-ligand and demethylating agents on cell growth is a general phenomenon common to all types of myeloid neoplasms. However, we found that the cooperative effects of the FAS-ligand with 5-azacytidine and decitabine are specific for neoplastic MCs, as no such cooperative effects were seen in the other myeloid leukemia models analyzed, that is, AML and CML.

As ASM and MCL are highly drug-resistant neoplasms, several attempts have been made to develop new effective therapeutic concepts.[11-17] One approach is to apply kinase blockers capable of suppressing the kinase activity of KIT D186V, such as PKC412 (midostaurin). We asked whether 5-azacytidine and decitabine would down-regulate expression of KIT D816V. However, no effects of the demethylating agents on KIT expression were found. Next, we asked whether 5-azacytidine or decitabine would cooperate with PKC412 in producing growth inhibition or apoptosis in neoplastic MCs. Indeed, when applied at a fixed concentration of 200nM, PKC412 was found to promote the growth-inhibitory effects of 5-azacytidine and decitabine on HMC-1 cells in an additive fashion. However, no synergistic drug interactions, neither on growth nor on survival of HMC-1 cells, were seen in this study.

In advanced SM including ASM and MCL, researchers are seeking novel drugs that may be capable of counteracting the devastating growth of MCs in ASM and MCL. In our study, pharmacologically meaningful concentrations of 5-azacytidine and decitabine were found to induce apoptosis in HMC-1 cells, including the HMC-1.2 subclone that exhibits the drug-resistant KIT mutant D816V. To the best of our knowledge this is the first study reporting antineoplastic effects of demethylating agents on human neoplastic MCs. In addition, our report is the first to describe that the death regulator *FAS* is hypermethylated in neoplastic MCs and that 5-azacytidine and decitabine can induce demethylation and thus reexpression of FAS. Whether these effects can be confirmed in clinical trials in patients with ASM and MCL, remains to be determined.

Acknowledgments

Authorship

Contribution: V.G. performed key staining, cell growth, and siRNA experiments and wrote parts of the paper; H.H. contributed cell growth and flow cytometry staining experiments; G.H. and S.Z-M. performed MSP, bisulfite genomic sequencing, EpiTect methyl qPCR array analyses, methylation-sensitive melting curve analyses, and qPCR experiments; B.P. contributed Western blot and qPCR experiments; E.H. contributed TUNEL staining experiments; K.B. contributed cell isolation and culture as well as flow cytometry experiments; K.S. and W.P. performed ³H-thymidine uptake experiments; S.C.-R. performed qPCR experiments; I.M. cultured and provided primary human cord blood–derived MCs; H.K. performed qPCR and siRNA experiments; and P.V. contributed logistic and budget support and wrote and approved the paper.

Conflicts-of-interest disclosure: P.V. is consultant of a Novartis PKC412 trial and received a Research Grant from Novartis. The remaining authors declare no competing financial interests.

Correspondence: Peter Valent, Dept of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; e-mail: peter.valent@meduniwien.ac.at.

References

1. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. *Br J Haematol*. 2003;122(5):695-717.

2. Akin C, Metcalfe DD. Systemic mastocytosis. *Annu Rev Med*. 2004;55:419-432.

3. Valent P, Horny H-P, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of "Year 2000 Working Conference on Mastocytosis". *Leuk Res*. 2001;25(7):603-25.

4. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. *Eur J Clin Invest*. 2007;37(6):435-453.

5. Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (Mast cell disease). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. In: Swerdlow SH, Campo E, Harris LH, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JM, eds. *Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: IARC Press; 2008:2:54-263.

6. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. *Proc Natl Acad Sci U S A*. 1995;92(23):10560-10564.

7. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. *Nat Genet*. 1996;12(3):312-314.

8. Fritsche-Polanz R, Jordan JH, Feix A, et al. Mutation analysis of *C-KIT* in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. *Br J Haematol*. 2001;113(2):357-364.

9. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. *Blood*. 2009;113(23):5727-5736.

10. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. *J Allergy Clin Immunol*. 2009;124(3):514-521.

11. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. *Leuk Res*. 2004;28(3):249-257.

12. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. *Blood*. 2003;102(13):4270-4276.

13. Gotlib J, Berubé C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. *Blood*. 2005;106(8):2865-2870.

14. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: four cases. *Eur J Haematol*. 2008;80(5):456-458.

15. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. *Clin Cancer Res*. 2008;14(12):3906-3915.

16. Valent P, Ghannadan M, Akin C, et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic MCs and evaluation of arising treatment concepts. *Eur J Clin Invest*. 2004;34(2):41-52.

17. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. *Best Pract Res Clin Haematol*. 2006;19(3):595-615.

18. Issa JP. DNA methylation as a therapeutic target in cancer. *Clin Cancer Res*. 2007;13(6):1634-1637.

19. Esteller M. Epigenetics in cancer. *N Engl J Med*. 2008;358(11):1148-1159.

20. Sharma S, Kelly TK, Jones PA. Epigenetics in Cancer. *Carcinogenesis*. 2010;31(1):27-36.

21. Silverman LR, Mufti GJ. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. *Nat Clin Pract Oncol*. 2005;2(1):12-23.

22. Müller CI, Rüter B, Koeffler HP, Lübbert M. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. *Curr Pharm Biotechnol*. 2006;7(5):315-321.

23. Kuendgen A, Lübbert M. Current status of epigenetic treatment in myelodysplastic syndromes. *Ann Hematol*. 2008;87(8):601-611.

24. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive

chemotherapy in patients with higher risk myelo-dysplastic syndrome: comparison with historical experience. *Cancer*. 2007;109(6):1133-1137.

25. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223-232.

26. Wijermans PW, Rüter B, Baer MR, Slack JL, Saba HI, Lübbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). *Leuk Res*. 2008;32(4):587-591.

27. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies. *Blood*. 2010;116(19):3735-3742.

28. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. *Int Arch Allergy Immunol*. 2002;127(2):140-142.

29. Mirkina I, Schweighoffer T, Kricek F. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. *Immunol Lett*. 2007;109(2):120-128.

30. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. *Leuk Res*. 1988;12(4):345-355.

31. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human MCs bearing wild-type or mutated c-kit. *Exp Hematol*. 2003;31(8):686-692.

32. Gleixner K, Mayerhofer M, Aichberger K, et al. PKC412 inhibits in vitro growth of neoplastic human MCs expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and

cladribine (2CdA), and evaluation of cooperative drug effects. *Blood*. 2006;107(2):752-759.

33. Kondo R, Gleixner KV, Mayerhofer M, et al. Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic MCs. *Blood*. 2007;110(2):661-669.

34. Gleixner KV, Ferenc V, Peter B, et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. *Cancer Res*. 2010;70(4):1513-1523.

35. Sambrook J, Fritsch EF, Maniatis T. Isolation of DNA from mammalian cells: Protocol I. In: *Molecular Cloning: A Laboratory Manual*. Vol 2. New York, NY: Cold Spring Harbor Laboratory Press; 1989:9-16.

36. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci U S A*. 1996;93(18):9821-9826.

37. Heller G, Weinzierl M, Noll C, et al. Genome-wide microRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. *Clin Cancer Res*. 2012;18(6):1619-1629.

38. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. *Leukemia*. 2009;23(6):1019-1028.

39. Schnekenburger M, Grandjenette C, Ghelfi J, et al. Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. *Biochem Pharmacol*. 2011;81(3):364-378.

40. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. *PLoS One*. 2011;6(3):e17388.

41. Petak I, Danam RP, Tillman DM, et al. Hyper-

methylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. *Cell Death Differ*. 2003;10(2):211-217.

42. Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen YH. decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. *Leuk Res*. 2003;27(11):999-1007.

43. Hirata H, Hinoda Y, Nakajima K, et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. *Int J Cancer*. 2011;128(8):1793-1803.

44. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2′-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. *Leuk Res*. 2010;34(3):364-372.

45. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. *PLoS One*. 2010;5(2):e9001.

46. Ruiz-Magaña MJ, Rodríguez-Vargas JM, Morales JC, Saldivia MA, Schulze-Osthoff K, Ruiz-Ruiz C. The DNA-methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells. *Int J Cancer*. 2012;130(5):1195-1207.

47. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. *Mol Cancer Ther*. 2008;7(9):2998-3005.

48. Giraud S, Bessette B, Boda C, et al. In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats. *Int J Oncol*. 2007;30(1):273-281.

49. Liu Z, Liu R, Qiu J, et al. Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response. *Cell Mol Immunol*. 2009;6(3):167-174.